MPDL3280A in Patients with Metastatic Bladder Cancer

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, discusses the results of a phase I study that examined the utilization of the anti-PD-L1 antibody MPDL3280A as treatment for patients with metastatic bladder cancer.

Clinical Pearls:

• MPDL3280A reduced tumors in 43% of patients with previously treated PD-L1-positive metastatic bladder cancer, the study results showed.
• MPDL3280A was well tolerated during the study.
• More research needs to be done in order to determine which patients will benefit the most from this treatment.